A scientist who decided the most interesting molecule in the room was the deal.
Most people who earn a Harvard PhD in chemistry spend the next thirty years defending it. Scott Peterson did something stranger. He used it, then walked away from the bench it was built on, and rebuilt his career around the part of biotech that has nothing to do with pipettes: the deal, the partnership, the term sheet, the slow art of turning a discovery into a business.
Today he is the Chief Business Officer of T-Cypher Bio, an Oxford-based company with an unfashionably large ambition. T-Cypher is trying to decode how immune cells talk to one another at the most intimate point of contact - the immune synapse, the 3D handshake between a T cell and its target - and to build next-generation TCR therapeutics out of what it learns. The science is dense. The datasets are enormous. Somebody has to translate all of that into language a partner, an investor, or a pharma board will sign their name beneath. That somebody is Peterson.
It is a job that rewards a rare kind of person: fluent enough in the chemistry to know when a claim is real, and fluent enough in finance to know what it is worth. Peterson is one of the few who can hold both at once.
The North Dakota to Cambridge line
The geography is its own small story. Peterson did his undergraduate work at North Dakota State University, a long way from the coastal biotech corridors where he would eventually make his name. From there he went to Harvard, where he spent the early 2000s earning a doctorate in chemistry. The recommendations from those years describe a familiar archetype - the organized, structured lab worker who strengthens whatever group he joins. Useful traits for a chemist. It turns out they are even more useful for a dealmaker.
His first professional life was spent at the bench, as a medicinal chemist. At Merck he worked on drug discovery programs and the licensing agreements that surrounded them. That last detail matters more than it looks. Most chemists never see the contract that governs the molecule they are building. Peterson did - and somewhere in the overlap between the science and the paperwork, he found the work he actually wanted to do.
The crossover
The leap from research to business development is one people talk about more than they make. The skills look adjacent and turn out to be different sports. Peterson made the jump anyway, and then kept making it pay.
At Intarcia Therapeutics he served as Executive Director of Corporate Development and helped build the company's development pipeline - the unglamorous, foundational work of deciding what a biotech will actually try to bring to patients. He went on to lead business development at Spero Therapeutics. Then came Dewpoint Therapeutics, the buzzy biomolecular-condensates company, where he rose to Senior Vice President of Corporate Development during a stretch when Dewpoint was striking the kind of partnerships that put condensate biology on the industry map.
Why T-Cypher, and why now
T-Cypher Bio is the natural endpoint of that arc. Spun out of the University of Oxford and backed by Oxford Science Enterprises, the company sits exactly where Peterson is most valuable: at the seam between genuinely novel science and the commercial reality that decides whether it ever reaches anyone. Its platform fuses wet-lab and computational methods to generate massive datasets about immune-system biology, with the goal of identifying disease-specific targets for solid tumors and selected autoimmune conditions.
That is a pitch that only works if the person delivering it understands both halves. A finance executive who cannot read the biology oversells. A scientist who cannot read a balance sheet undersells. Peterson is the rare third option - and as Chief Business Officer he owns the company's partnering strategy, its corporate development, and the long campaign of turning a platform into a pipeline of deals.
The setup is itself a small piece of trivia. Peterson is based in the Greater Boston area, the densest biotech cluster on earth, while T-Cypher is headquartered in Oxford. He works the Atlantic the way other executives work a hallway - a transatlantic commercial brain for a quintessentially British science story.
The throughline
Look across Intarcia, Spero, Dewpoint and T-Cypher and a pattern appears. Peterson keeps choosing companies where the science is hard and unproven and the commercial path is anything but obvious. Sustained-release drug delivery. Antibiotics. Condensate biology. Now TCR therapeutics and the immune synapse. None of these are easy stories to sell. All of them need someone who can make the hard thing legible.
That is the quiet specialty hiding inside his title. Not "business development" in the generic sense, but the specific talent for standing between a brilliant, complicated platform and the people who have to bet money on it - and making the conversation honest in both directions. He has been doing it for two decades, and the through-line is consistent enough to look almost deliberate.
The colleague who called him methodical was describing a chemist. They could not have known they were also describing how he would run a deal twenty years later: organized, structured, patient, the kind of person who strengthens the group. In biotech, where most discoveries die in the gap between the lab and the market, that is not a soft skill. It is the whole job.
The platform he has to sell
To understand the size of Peterson's task at T-Cypher, look at what the company is actually building. Its public description is unusually candid about the difficulty: a proprietary platform that fuses wet-lab experimentation with computational modeling to generate massive datasets, then mines those datasets for the precise 3D interactions between proteins that govern how immune cells recognize disease. The trademarks alone - T-Cypher, T-C-alpha, T-Synapse - read like a map of the problem they are trying to own. This is the immune synapse rendered as data, at a resolution most of the field has never had.
From that data the company hunts for disease-specific targets, the molecular signatures that distinguish a tumor cell or a misbehaving immune cell from a healthy one. The goal is to engage the immune system more precisely than the blunt instruments that came before. It is the kind of science that excites researchers and terrifies anyone who has to put a number on it, because the path from a beautiful dataset to an approved therapy is long, expensive, and littered with companies that had beautiful datasets too. Peterson's job is to keep that path commercially alive while the science does its slow work.
The craft nobody puts on a poster
Business development in biotech is easy to caricature and hard to do. The caricature is the person in the good suit who shows up after the scientists have done the real work. The reality is closer to translation under pressure: taking a platform whose value lives in probabilities and timelines, and converting it into terms a counterparty will accept without either side feeling cheated. Get it wrong in one direction and you give the company away. Get it wrong in the other and the deal never closes and the runway runs out.
What separates Peterson is that he negotiates like someone who used to make the thing on the table. He knows which claims in a data package are load-bearing and which are decoration. He knows the difference between a result that will replicate and one that looks good in a slide. That instinct is not teachable in a finance course - it is the residue of years spent at the bench, watching experiments fail in all the ordinary ways. It is why a recommendation written for a chemist turned out to describe a dealmaker so precisely.
A transatlantic experiment
There is a structural curiosity worth dwelling on. T-Cypher is Oxford to its core - born from University of Oxford technology, backed by Oxford Science Enterprises, run from the science cluster south of the city. Peterson, meanwhile, operates from Greater Boston, the one place on the planet with a denser concentration of biotech capital and talent. That is not an accident of biography so much as a feature of the role. A company built on British academic science still has to raise money and strike partnerships in a market where many of the largest checks are written in dollars. Having a Chief Business Officer who lives inside that market, and who has spent two decades earning its trust, is a quiet strategic advantage that does not show up on any org chart.
It also says something about how Peterson sees the work. The interesting biology can come from anywhere - Oxford, Cambridge, a spin-out nobody has heard of. The commercial machinery that decides whether that biology survives is concentrated and clubby and unforgiving. His career has been a long apprenticeship in that machinery, and at T-Cypher he is pointing all of it at a single, audacious bet on the immune synapse.
Whether that bet pays off will be decided by science he does not control and timelines no one can promise. What he controls is the translation - the steady, methodical work of making a hard, important platform legible to the people who can fund its future. He has been rehearsing for this exact role since the day a Harvard chemist decided the most interesting molecule in the room was the deal.